logo
Brain Cell Transplant Slows Rare Neurodegenerative Disease

Brain Cell Transplant Slows Rare Neurodegenerative Disease

Medscape4 days ago
Replacing mutant microglia with healthy donor-derived microglia has emerged as a promising treatment for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
In a small study of eight patients with ALSP, replacing dysfunctional microglia with normal microglia using traditional bone marrow transplantation (BMT) halted the progression of ALSP and improved neurologic function.
'The critical next step is to validate these results in a larger clinical trial, which is already underway,' principal investigator Bo Peng, PhD, professor, Institute for Translational Brain Research, Fudan University in Shanghai, told Medscape Medical News .
The study was published online on July 10 in Science .
From Mice to Men
ALSP is a rare, progressive neurological disease with an average age of onset of 43 years and an average life expectancy of only 3-5 years after symptoms begin. There is no cure and there are few treatments.
ALSP is caused by mutations in the colony-stimulating factor 1 receptor gene (CSF1R), which is critical to development and survival of microglia. Mutations in this gene lead to microglial dysfunction and reduced numbers of these key brain immune cells.
In earlier work, Peng and his team developed mouse models of ALSP which exhibit hallmark features of the disease including reduced numbers of microglia, myelin abnormalities, axonal swelling and motor impairments, and cognitive decline.
To test whether microglial replacement could alter disease progression in mice with ALSP, the investigators tested two approaches: traditional BMT and microglia replacement by BMT (Mr BMT), a protocol that combines pharmacological depletion of microglia with traditional BMT.
Both approaches effectively replaced mutant microglia with wild-type counterparts and successfully reversed myelin defects, axonal swellings, and motor and cognitive impairments in the animals.
To translate this to the clinic, they performed traditional BMT in eight patients with ALSP. Although traditional BMT alone typically does not achieve efficient Mr in healthy brains, the inherent CSF1R deficiency in patients with ALSP creates a 'competitive disadvantage' for the recipient's resident microglia, allowing traditional BMT to achieve effective replacement, the researchers explained in their paper.
In the 2 years following Mr, MRI and clinical evaluations indicated 'halted disease progression, preserved motor function, and stabilized cognitive abilities,' the team reported. By contrast, untreated patients with ALSP exhibited rapid worsening of brain pathology over a shorter time frame.
The findings in these eight patients also provide a 'mechanistic explanation' for a prior clinical case in which an individual with ALSP, initially misdiagnosed with adult-onset metachromatic leukodystrophy, exhibited long-term stabilization after traditional BMT.
'While the path forward is active with the ongoing trial, traditional BMT becoming a widely accessible 'clinic-ready' standard treatment for ALSP is still estimated to be several years away, contingent upon successful trial outcomes, long-term safety data, and subsequent regulatory approvals,' Peng told Medscape Medical News .
Beyond ALSP
Peng also said Mr 'holds significant theoretical promise' for treating other neurological diseases involving microglial dysfunction, including Alzheimer's disease (AD).
'Genome-wide association studies have identified TREM2 as one of the major risk genes in sporadic AD. TREM2 mutation may cause or accelerate the progression of AD. In a 2020 paper in Cell Reports , we proposed that we can replace the TREM2 -mutated microglia with TREM2 -normal cells to treat this disease,' Peng added.
In a Science perspective , Siling Du, PhD, and Jonathan Kipnis, PhD, with the Brain Immunology and Glia Center, Washington University in St Louis congratulated Peng and colleagues for demonstrating in humans that 'correcting a microglial gene defect through cell replacement can arrest disease progression.'
Du and Kipnis agreed that the potential implications of this research extend beyond ALSP.
For example, a recent study demonstrated that microglial replacement can also rescue pathology in a mouse model of Krabbe disease, a monogenic neurodegenerative disorder caused by mutations in the gene encoding galactosylceramidase.
In addition, traditional BMT has also been shown to arrest disease progression in a mouse model of Rett syndrome — a severe neurodevelopmental condition caused by loss-of-function mutations in the gene encoding methyl-CpG binding protein 2.
'Together, these findings highlight the therapeutic potential of microglial replacement in modifying the course of monogenic neurological diseases,' Du and Kipnis said.
Looking ahead, they said it will be important to establish the optimal donor cell source to achieve 'scalable, safe, and durable microglial replacement.'
'It is also not yet clear whether the systemic toxicity caused by pretransplant conditioning can be minimized without compromising engraftment. Future strategies must strike a balance between replacement efficiency, systemic toxicity, and the functional competence of engrafted cells,' they wrote.
'Moving forward, it may ultimately become possible to reprogram the brain's immune landscape from within and find the best microglial replacement approach not only for microgliopathies but for a spectrum of neurological diseases,' Du and Kipnis concluded.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Turkey unveils domestically built hypersonic missile
Turkey unveils domestically built hypersonic missile

Yahoo

time4 hours ago

  • Yahoo

Turkey unveils domestically built hypersonic missile

STORY: :: Turkey unveiled its first domestically built hypersonic missile at an international arms fair :: July 22, 2025 :: Istanbul, Turkey :: The missiles typically launch a warhead that travels at five times the speed of sound at low altitudes Footage released by the Turkish missile manufacturer Roketsan showed the new weapon, known as the Tayfun Block-4, being showcased at the International Defence Industry Fair (IDEF). Hypersonic missiles typically launch a warhead that travels at more than five times the speed of sound or about 3,850 mph, often maneuvering at relatively low altitudes. The United States, China, Russia and other countries have also been developing hypersonic weapons in recent years.

An Inventor Is Injecting Bleach Into Cancerous Tumors—and Wants to Bring the Treatment to the US
An Inventor Is Injecting Bleach Into Cancerous Tumors—and Wants to Bring the Treatment to the US

WIRED

time4 hours ago

  • WIRED

An Inventor Is Injecting Bleach Into Cancerous Tumors—and Wants to Bring the Treatment to the US

Xuewu Liu, a Chinese inventor who has no medical training or credentials of any kind, is charging cancer patients $20,000 for access to an AI-driven but entirely unproven treatment that includes injecting a highly concentrated dose of chlorine dioxide, a toxic bleach solution, directly into cancerous tumors. One patient tells WIRED her tumor has grown faster since the procedure and that she suspects it may have caused her cancer to spread—a claim Liu disputes—while experts allege his marketing of the treatment has likely put him on the wrong side of US regulations. Nonetheless, while Liu currently only offers the treatment informally in China and at a German clinic, he is now working with a Texas-based former pharmaceutical executive to bring his treatment to America. They believe that the appointment of Robert F. Kennedy Jr. as health secretary will help 'open doors' to get the untested treatment—in which at least one clinic in California appears to have interest—approved in the US. Kennedy's Make America Healthy Again (MAHA) movement is embracing alternative medicines and the idea of giving patients the freedom to try unproven treatments. While the health secretary did not respond to a request for comment about Liu's treatment, he did mention chlorine dioxide when questioned about President Donald Trump's Operation Warp Speed during his Senate confirmation hearing in February, and the Food and Drug Administration recently removed a warning about substance from its website. The agency says the removal was part of a routine process of archiving old pages on its site, but it has had the effect of emboldening the bleacher community. 'Without the FDA's heavy-handed warnings, it's likely my therapy would have been accepted for trials years earlier, with institutional partnerships and investor support,' Liu tells WIRED. He says he wrote to Kennedy earlier this year urging him to conduct more research on chlorine dioxide. 'This quiet removal won't immediately change everything, but it opens a door. If mainstream media reports on this shift, I believe it will unlock a new wave of serious [chlorine dioxide] research.' For decades, pseudoscience grifters have peddled chlorine dioxide solutions—sold under a variety of names, such as Miracle Mineral Solution—and despite warnings and prosecutions, have continued to claim the toxic substance is a 'cure' for everything from HIV to Covid-19 to autism. There is no credible evidence to back up any of these claims, which critics have long labeled as nothing more than a grift. The treatments typically involve drinking liquid chlorine dioxide on a regular basis, using solutions with concentrations of chlorine dioxide of around 3,000 parts per million (ppm), which is diluted further in water. Liu's treatment, however, involves a much higher concentration of chlorine dioxide—injections of several milliliters of 20,000ppm—and, rather than drinking it, patients have it injected directly into their tumors. Liu claims he has injected himself with the solution over 50 times and suffered no side effects. 'This personal data point encouraged me to continue research,' he says.

What Factors Influence a Patient's Success on GLP-1s?
What Factors Influence a Patient's Success on GLP-1s?

Medscape

time6 hours ago

  • Medscape

What Factors Influence a Patient's Success on GLP-1s?

Longer treatment duration, not having diabetes, and using semaglutide were among the factors associated with better weight reduction over 12 months among patients taking GLP-1 receptor agonists (RA), a cohort study suggested. 'Treatment responses differ among patients receiving GLP-1 RAs, and the weight fluctuations and associated factors following [their] use have not been adequately characterized,' Linong Ji, MD, of Peking University People's Hospital in Beijing, China, told Medscape Medical News . The findings, published online in Diabetes, Obesity and Metabolism , 'may provide novel insights into weight fluctuations after GLP-1 RA treatment in a real-world setting,' he said, potentially advancing the development of individualized strategies for patients. 'Corroborates Other Studies' Researchers conducted a real-world, single-center, retrospective study of 679 patients with overweight or obesity who initiated GLP-1 RA treatment between November 2022 and October 2024. At baseline, participants had a mean age of 37 years, and 31% were men. The mean BMI was 33.4, and 21% were diagnosed with diabetes. The GLP-1 RAs used in the study included semaglutide (Ozempic), liraglutide (Victoza), lixisenatide (Lyxumia), beinaglutide (Yishengtai), exenatide (Bydureon), dulaglutide (Trulicity), and PEG-loxenatide (Fulaimei). All were available for participants with both type 2 diabetes (T2D) and overweight/obesity. For participants with overweight/obesity but without T2D, only Ozempic or Victoza were routinely prescribed, with off-label documentation and informed consent. Weight measurements were collected during in-person clinic visits, and weight fluctuation curves were stratified into three phenotypes — Successful Weight Reduction, Remaining Stable, and Weight Regain. Subsequently, the association between potential influencing factors and weight fluctuations was estimated by univariate and multivariate logistic regression. Subgroup analyses were performed in participants with obesity, prediabetes, and in those using liraglutide or semaglutide. Researchers found significant differences in the duration of GLP-1 RA treatment across groups at the 3-, 6-, and 12-month follow-ups. The Successful Weight Reduction group had a significantly longer duration of GLP-1 RA treatment than the Remaining Stable group and a longer duration at both the 6- and 12-month follow-ups than the Weight Regain group. Diabetes status also showed group differences. At both the 3- and 6-month follow-ups, the proportion of patients with T2D in the Successful Weight Reduction group was lower than in the Remaining Stable group. Types of GLP-1 RAs varied between groups, and at the 3- and 6-month follow-ups, the Successful Weight Reduction group was more likely to have initiated treatment with semaglutide than the Remaining Stable group. Patients with a longer duration of GLP-1 RA treatment (odds ratio [OR], 1.014) and higher Homeostasis Model Assessment of Beta-Cell Function levels (OR, 4.912) were more likely to achieve successful weight reduction at the 12-month follow-up. Nondiabetic status (OR, 2.176) and using semaglutide (OR, 2.138) were associated with successful weight reduction at the 6-month follow-up. In addition, a higher percentage of body fat in both men (OR, 3.990) and women (OR, 2.266) was associated with successful weight reduction. The weight regain group had a higher baseline estimated glomerular filtration rate than the Successful Weight Reduction group and the Remaining Stable group at 3-month follow-up, especially among participants with prediabetes. Ji said this finding surprised him. Patients with obesity often exhibit a state of renal hyperfiltration, characterized by elevated renal plasma flow and glomerular filtration rate, which can be reversed by weight reduction. The finding suggests that patients with renal hyperfiltration might be less likely to experience durable weight reduction, Ji said. 'However, few studies have revealed similar observations. Therefore, further validations and investigations are still needed for this finding.' Furthermore, the team found a positive nonlinear association of serum creatinine with successful weight reduction at 12 months — a finding that will also require additional investigations to examine the mechanism underlying the association. Overall, Ji concluded that while longer duration of GLP-1 RA treatment using semaglutide, nondiabetic status, and higher percentage of body fat might be associated with better weight reduction, 'basal metabolic rate, skeletal muscle mass, muscle mass of the abdomen and limbs, and serum creatinine were nonlinearly associated with the probability of successful weight reduction.' Randy Seeley, MD, Henry King Ransom Endowed Professor of Surgery, Internal Medicine, and Nutritional Sciences at the University of Michigan School of Medicine, Ann Arbor, Michigan, and director of the National Institutes of Health-funded Michigan Nutrition Obesity Research Center, told Medscape Medical News , 'The main results of the study agree with what the field has already seen. Although it is a relatively small study, it corroborates other larger studies,' said Seeley, who was not involved in the study. This work was supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project. Ji reported receiving fees for lecture presentations and for consulting from AstraZeneca, Merck, Metabasis, MSD, Novartis, Eli Lilly and Company, Roche, Sanofi-Aventis, and Takeda. Seeley reported that his lab has worked with both Novo and Lilly (and others trying to enter the space), and he has also served as a paid consultant for both of those companies (and others trying to enter the space).

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store